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Summary In recent years, vagal nerve stimulation (VNS) has been proposed as a
possible way to improve the control of refractory (partial and generalized) seizures.
To date, however, there is no complete understanding of the underlying mechanism
for this action nor are there any available guidelines or criteria for the selection of
those candidates that might bemost suitable for this kind of neuromodulating surgery.
This report presents evidence that should be helpful in defining the clinical criteria
for using VNS for the treatment of refractory seizures. We report on 17 patients with
severe partial refractory epilepsy and polymorphous seizures, who have been oper-
ated on previously or who were excluded from epilepsy surgery and for whom, at
least, one seizure type has been electrographically recorded. Sixteen of these
patients also had falling seizures. Our objective was to identify responders and to
correlate the outcome of their seizures with the EEGraphic onset of their seizure.
Follow-up ranged from 4 to 9 years.
The results of this study indicate a significant reduction of seizures in only four
patients and better outcome in patients where the onset of seizure activity occurred
in the temporal area. Patients with frontal or frontocentral seizures resulted in the
poorest outcomes. In four patients with Lennox—Gastaut syndrome VNS produced no
significant reduction of seizures, while falling seizures decreased significantly in three
patients with retropulsive falls.
These results of this small series of patients suggest that VNS might be more
suitable in patients with temporal rather than frontal or central seizure onset. Further
studies are required to support this hypothesis.
# 2006 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.* Corresponding author. Tel.: +39 02 23942216; fax: +39 02 70600775.
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Pathological synchronization of cortical activity
plays a major role in the generation of seizures.
Because antiepileptic drugs are not always effec-
tive in counteracting neuronal hyper-excitability
and pathological synchronization, there are about
30% of the epileptic patients who are not satisfac-
torily controlled by medical therapy.1 Traditional
epilepsy surgery, i.e. that kind of surgery aiming to
the epileptogenic zone resection or deconnection,
is unfortunately not able to control seizures in the
case of every intractable epilepsy. In addition, side
effects of this kind of surgery are not negligible.
For this reason alternative surgical strategies aim-
ing to modulate neuronal activity of deep brain
areas has been suggested. Thalamic2 and subtha-
lamic3 stimulation have been found to produce
encouraging results, but the number of patients
is small and the method is further limited by the
need for very precise stereotactic method for
electrodes implantation.4 Further information
will be needed to assess the suitability and safety
of this therapeutic alternative.
In the 1990s, vagal nerve stimulation (VNS) was
proposed as a therapeutic strategy for the control of
seizure activity. Though the exact mechanism of this
strategy continues to remain uncertain, there is
evidence that suggests an involvement of synaptic
and neuro-chemical mechanisms.5,6
Numerous data on animals suggest an antiepilep-
tic effect of VNS. In cats it is known to produce
different effects on EEG activity and on sleep pat-
terns, depending on the stimulus parameters that
are used. High frequency stimulation has been
demonstrated to desynchronize cortical activity
and a putative mechanism of afferent activation
of the nucleus of the solitary tract and the ascending
reticular system was suggested.7—9 Electrical stimu-
lation of the vagus nerve has been shown to abort
induced seizure activity in dogs 10 and also in pri-
mates.11 While in cats, it has been shown to delay
amygdaloid kindling.12
In rats, more recent data suggests that stimula-
tion of the myelinated A- and B-fibers of the vagus
nerve is able to suppress seizure activity.13 Zagon
and Kemeny proposed that neuronal excitability is
reduced by a slow hyperpolarization of cortical
pyramidal cells.14
In man vagal nerve has afferent fibers from
lungs, heart, aorta, gastrointestinal tract and
aortic chemoreceptors, projecting to the nucleus
tractus solitarius. From this nucleus there are poly-
synaptic projections to different structures of the
posterior fossa, but even to the noradrenergic
and serotonergic neuromodulatory system, throughthe locus coeruleus. This nucleus is the major
source of norepinephrine, and its interactions
with vagal nerve is probably relevant, considering
the antiepileptic effect of this aminoacid. The
nuclei of the vagal nerve are also connected with
hypothalamus, dorsal raphe, nucleus ambigus,
amygdala and thalamus (6, 15).
Positron-emission tomography (PET) induced
significant increase in CBF in right thalamus and
right posterior gyri, in the hypothalami and in
insular cortex From recent studies on f-MRI in
depressed patients, who received VNS, show an
immediate activation of the orbitofrontal region,
insula and medial temporal lobe.19 VNS at high
frequency (20 Hz) is known to have a greater
effect than slow frequency (5 Hz)16 inducing
changes in cerebral blood flow with significant
increases being found in orbitofrontal gyri, entorh-
inal cortex and temporal pole,17 and concomitant
decreases have been found in the amygdala, hip-
pocampus and posterior cyngulate gyrus. These
structures, amygdala, hippocampus and posterior
cyngulate gyrus, which are commonly involved in
partial epilepsies, seem to have a reduction of
synaptic activity during VNS, which may account
for a lower probability of seizure onset in those
areas (6).
Studies on the induction of immunoreactivity of
‘fos’, nuclear labelled protein, that has been used
during VNS of the rat brain, has produced results
which suggest that an antiepileptic effect may be
linked to an elevation of ‘fos’ protein in forebrain
structures.18 An increase of norepinephrine has also
been shown to play a role in controlling seizures
after VNS. To add even more complexity to an
already complicated mechanistic understanding of
VNS is the finding that this kind of neuromodulation
also exerts an effect on major clinical depression.19
The mechanism of action of VNS is still debated
and under study, but we assume that it may be
mediated by a decreased synchrony of synaptic
cortical activity, mediated by the thalamus, by an
intermittent synaptic activation in the insula and
hypothalamus, and by intermittently decreased
activity in amygdala, hippocampus, and other lim-
bic components. Also the intermittent release of
norepinephrine contributes to the antiepileptic
effect of VNS (6).
Interestingly, the vagal nerve stimulator is actu-
ally a device, developed and produced by Cybero-
nics Inc., that grew out of the intense research and
development work that has been directed to the
development of safe and effective cardiac pace-
makers. It is programmable pulse generator, and
the VNS is connected to bipolar electrodes that have
been surgically positioned around the left vagus
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surgical technique that has been used successfully
in the treatment of both adults and children
suffering from partial refractory epilepsy.20,21
Surgery is performed under general or local ana-
esthesia using a standardized technique that typi-
cally lasts 60—80 min. Patients are routinely
discharged on either the day of surgery or the
following day and, to date, there have been no
reports of any significant complications using VNS.
The results on using VNS to control seizure fre-
quency have been encouraging. In most reports that
are found in the literature, almost 35% of patients
treated had a reduction of more than 50% of sei-
zures, and the percentage of responders increases in
the first year of stimulation, reaching as high as
60%.15,22—24
The outcomes that have been reported are, how-
ever, quite variable. In the description of Morris
et al.25 fits are significantly lessened in 50—90% of
patients. Binnie et al.26 report a lower percentage
of responders (35%), although there are indications
that a selection factor may account for this signifi-
cant difference. In children, however, the results
appear to be even better, with the percentage of
success reaching even higher than a 90% seizure
reduction (in 23% of the children studied).27 In all
of these reports, there is a greater seizure reduction
when the VNS is more prolonged.23 The finding of
better results in the first year of stimulation may be
suggestive of progressive changes in stimulation
setting, although the reason remains unclear.
A review of the literature on VNS provides not
indication or suggestion of which are the best can-
didates for VNS. Typically, adults and children with
partial refractory epilepsy, with or without secon-
darily generalization, and who are not candidates
for resective epilepsy surgery have been the
patients who have been referred for this procedure.
And there has been little or no attention paid to the
predictive value of the electroclinical ictal pattern
that was involved.
For these reasons, we have therefore selected a
group of 17 adult patients to be implanted for VNS.
All of these patients had intractable partial epilepsy
with falls found in 16 of these cases. In one case, the
patient had partial complex seizures and seconda-
rily generalized tonico-clonic morpheic seizures.
Falling seizures in partial epilepsies have differ-
ent pathogenesis and an ictal onset. Many of them
are observed in frontal epilepsies, although they can
be observed also in temporal epilepsy, and they
seem to be linked to a mechanism of secondary
bilateral synchrony.28 These seizures are very dis-
abling and have a poor prognosis. On the basis of
existing experimental evidence, VNS should beexpected to interrupt the ictal diffusion and lead
to a selective reduction of epileptic falls. Falling
seizures can, however be very different. They may
be myoclonic, tonic, tonico-postural, atonic at
onset, and with different EEGraphic patterns.
Our purpose, therefore, was to try to identify the
best candidates for the VNS implant and to verify
the effectiveness of VNS on epileptic falls.
The results of this study present data on the
EEG ictal onset site that arose as was the clinical
outcome in these patients following VNS.Methods
Seventeen adult patients (11 males and 6 females)
with intractable epilepsy were selected to be part
of this study (Table 1). After receiving approval
from our hospital’s ethical committee, and over a
5 year period from October 1995 to October 2000,
we began the process of implanting electrodes
in these 17 patients. Each of these patients was
then followed up over a period that ranged from 4
to 9 years. The mean age at the time of implantion
was 34 years (range 21—52), the mean age at the
time of the onset of epilepsy was 10 years (range
from 3 months to 39 years), and the mean duration
of the patient’s illness was 24 years (range 11—41).
Patients whose epilepsies were the result of either
progressive neurological disorders or evolutive
brain lesions were excluded from the study. We
also excluded any patients who were suffering
from any known gastric or cardiac illness.
We divided these patients into the following
categories: ‘symptomatic’, of which there were
eight cases (perinatal injury in four, cerebral mal-
formation in one, low grade tumor in one, subar-
achnoid hemorrhage in one, cavernoma in one);
‘unknown etiology’, of which there were five
patients; and as ‘cryptogenic’, of which there were
four patients. This last category, ‘cryptogenic’,
included patients who showed a normal neurologic
examination and a normal MRI in contrast to the
‘unknown etiology’ group which showed a normal
MRI but also neurological signs and symptoms.
In five patients, the neurological examination
was normal while in five it disclosed focal neurolo-
gical signs that in three were found to be associated
to mental retardation. In five patients we found
signs of mild to severe mental deterioration and
in the remaining two patients mental retardation
was found to be associated to behavioral distur-
bances. The mean number of basal monthly seizures
was 83.8 (range 6.3—720 with a standard deviation
of 171.7). This mean number excludes clusters,
which we observed in 5 of the 17 patients. In all
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Table 1 Clinical features of patients
Patient Sex Age Onset Disease
duration
Etiology Neurologic examination Diagnostic MRI
BO1 F 47 19 28 Cryptogenic Normal Cerebellar atrophy (toxic)
BO2 M 30 8 22 Unknown Mild mental debility Normal
BO3 M 41 16 25 Oligoastrocytoma Normal Right T polar calcific lesion
BO4 M 30 3 MTHS 30 Aneurysm and
derived hydrocephalus
Severe mental
impairment, strabismus
Bifrontal poroencephaly
and enlargement
of frontal horns
BO5 M 44 9 35 Cavernous angioma Right nystagmus,
dysarthria, hypokinesia
Left cortical fronto
insular lesion with
hypointense ring
BO6 F 25 3 22 Unknown Severe behavioral
disturbances,
moderate mental debility
Normal
BO7 F 30 16 MTHS 29 Perinatal injury Moderate mental debility Diffuse cortical atrophy,
ventricular enlargement
BO8 F 33 13 20 Perinatal injury Right hemiplegia, mild
mental debility
Large left frontal
poroencephaly
BO9 M 30 10 20 Cryptogenic Normal Normal
B1O M 24 5 19 Perinatal injury Severe mental
impairment
Left ventricular
enlargement
B11 M 30 11.5 18.5 Cryptogenic Normal Diffuse cortical atrophy
B12 M 35 4 MTHS 35 Unknown Severe mental debility,
ataxia, hyporeflexia
Ventricular enlargement
B13 M 42 1 41 Perinatal injury Light ataxia and
dysmetria
Right parietooccipital
ulegyria
B14 M 52 39 13 Cryptogenic Normal Normal
B15 M 37 26 11 Unknown Mild mental debility,
behavioral disturbances
Normal
B16 F 27 8 19 Unknown Mental deterioration Normal
B17 F 21 8 MTHS 20 Complex cerebral
malformation
Moderate mental
disability
Partial agenesia of corpus
callosum, periventricular
right occipital heterotopia,
diffuse neuronal migration
disorderbut two patients we observed, at least, two dif-
ferent seizure types. Only one of these patients
experienced a brief aura of distress prior to some of
his seizures. In the other 16 cases there was an
immediate loss of contact that was followed by
versive or motor phenomena or automatisms, and
falling. A preoperative recording was obtained —
either in our Institute or elsewhere — for, at least,
one seizure type from every patient in the study. In
12 of the patients we studied falling was EEGra-
phically recorded. Table 2 reports typical ictal
patterns of our series.
Five patients received unsuccessful surgical
treatment prior to the VNS implant: patient B03
had a lesionectomy 3 years before implant for an
oligoastrocytoma that had no effect on seizure
frequency; patient B04, who was operated on for
a cerebral aneurysm and shunted for hydrocephalus
at the age of 3 months, developed epilepsy shortlyafter; patient B09 underwent a left precentral
cortectomy 3 years before VNS implant, after a
thorough presurgical study that involved seizure
recording with deep electrodes. This procedure
had no effect on seizure frequency, patient B11
was surgically treated for epilepsy with a tempo-
robasal posterior cortectomy 18 months before
the VNS implant that had no effect on seizure
frequency; and finally, patient B15 underwent
right frontopolar and frontomesial cortectomy
3.5 years before implant without any therapeutic
effect (Fig. 1).
The other patients were either refused or
excluded from epilepsy surgery for the following
reasons: (1) their type of epilepsy could not be
defined on the basis of the information that was
available; (2) the presence of synchronous bifro-
ntal ictal discharges in which there was no certain
signs of lateralization; (3) due to ictal involvement
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Table 2 Ictal EEG features
Patient Ictal pattern
B01 Right temporal posterior fast activity
B02 Bilateral diffuse sw sometimes preceded by
left or right temporoparietal attenuation
B03 Right frontotemporal attenuation and fast
activity
B04 Right frontal attenuation and fast activity
B05 Diffuse attenuation and fast activity
sometimes more evident on anterior
vertex and left centrotemporal region
B06 Diffuse slow waves with left frontotemporal
lateralization. Depth electrodes stimulation
induced ictal discharges on both
temporal regions
B07 Diffuse attenuation, followed by slow
waves and diffuse fast activity more
evident on left temporal area
B08 Left centroparietal attenuation and
centroparietooccipital fast activity
B09 Right diffuse attenuation and frontocentral
fast activity; stereoeeg showed the
involvement of left dorsolateral
frontal area and sma
B10 Diffuse fast activity more evident on
frontocentral regions
B11 Left temporal posterior fast activity;
stereoeegshowed a diffuse extension
of ictal discharge more tonic on left
temporobasal area
B12 Diffuse attenuation and fast frontal
bilateral activity
B13 Left posterior attenuation and fast
left frontocentral activity
B14 Left frontocentroparietal attenuation
followed by diffuse discharge
B15 Bifrontal and right temporal rapid activity;
stereoeeg shows a very large involvement
of right frontal region
B16 Diffuse attenuation and fast activity
followed by diffuse spikes
B17 Diffuse sw or spike and wavesof motor area; (4) due to severe mental retardation
or psychic disturbances; (5) because of bilateral
or polymorphous seizure activity.
VNS implantation was performed, under gen-
eral anaesthesia, in the upper left chest region
and the stimulating lead was attached to the left
vagus nerve in the neck. The technique used to
implant the pulse generator is similar to that
which is routinely used in the implantation of
cardiac pacemakers. Electrodes are placed
around the left vagus nerve at the level below
its branching into superior and inferior cervical
cardiac rami. In no cases did we experience any
complications following surgery and all patientswere discharged from the hospital 24 h after the
implantation procedure.
The only side effect of significance which was
reported by all patients was that of a voice altera-
tion during the ‘on’ period of stimulation. This
appeared to be related to the intensity of current
that was used and was usually present at the
moment that there was an increase of current.
Though all patients reported this effect it seems
to have been well tolerated it well and, as the
stimulation progressed this effect was clearly
reduced. Three patients began to cough every
time the output current was increased. This effect
also faded out with the passage of time and repeti-
tion. In one patient with Lennox—Gastaut syn-
drome (LNS) we observed a fecal and urinary
incontinence, associated with diarrhea, when
the output current was increased. This disap-
peared when there was a reduction of the intensity
of the output current.
We activated the generators 15 days after surgery
and the patients were initially controlled at 15 day
intervals. This was then increased to monthly inter-
vals and then to 3 month intervals. As time passed,
these controls would depend upon the clinical
results we observed although they were always
performed at least once every 6 months.
The standard stimulation paradigm was: Output current From 0.75 to 3.0 ma
 Signal frequency 30 Hz
 Pulse width 500 s
 Signal on time 30 s
 Signal off time 5 minOutput current was progressively modified
depending upon the clinical outcomes and the
subjects tolerance. We did not use a magnet to
activate an extra burst of stimulation at the time
of the onset of seizures in our patients because
no auras were reported (except in one case we
encountered) and the duration was too short. In
one patient, a family member did use the magnet
when the seizure began, and this seizure, was
shortened and less severe. In nine patients, we
switched our standard paradigm of stimulation to
rapid cycle parameters after a minimum of an
8 month interval after implantation, but when we
did this we found no satisfactory results.
The Rapid cycle paradigm was:Output current From 1.25 to 3 ma
Signal on time 7 s
Signal off time 20 sWe maintained this rapid cycle paradigm in only
three patients, while we were able to return to the
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Figure 1 Patient B03: recording of a partial seizure characterized by sudden loss of contact, followed by eyes and head
deviation to the left, smile and secondary generalization. On scalp EEG fast activity on right frontotemporal area may be
observed.standard stimulation paradigm–—with an increase
of output current, in five patients after 4—
10 months post-implant period. One patient was
not able to tolerate the VNS. He reported a marked
increase in seizures after less than one month of
stimulation at 1.5 milliampe`res (ma) that was
accompanied by an unacceptable hoarseness.
Wanting to discontinue stimulation, he refused to
try VNS even when we suggested lowering output
currents. We then removed the VNS system 5
months after its implantion.Results
The rather long follow-up of our patients indicate
a stable effect of VNS. The effect that we were
able to reach with the best stimulation paradigm
(normal or rapid cycle and with varying intensities)
was sustained with the passage of time. Only one
patient (B11) experienced anything that rese-
mbled a transitory benefit–—an almost complete
disappearance of falling seizures followed by a
rapid relapse to the seizure frequency seen during
the pre-implant period. We report our findings of
seizure reduction in terms attaining stable stimu-
lating conditions within a 6—9 months after sur-
gery. When we encountered unsatisfactory resultswith a normal cycle that was taken to the highest
tolerated intensity we would then typically switch
the VNS to a rapid cycle using the same level of
intensity we had been using. No significant differ-
ences were observed using these different stimu-
lation paradigms.
In four patients with cryptogenic partial epi-
lepsy, we found a reduction of more than 50% of
the total number of monthly seizures (Table 3). In
three of these patients the ictal recording indi-
cated initial changes in temporal regions. In all of
these patients falling seizures were decreased and
in three of them there was also a reduction in
minor seizures.
In four other patients, three of whom sympto-
matic, a less than 50% reduction of seizures was
observed; a significant reduction in falling seizures
was found in only two of them. In three of these
four patients the initial onset of seizures was found
in the temporal region.
In three patients of the reported on in Table 4,
seizure activity did not change significantly after
VNS. Two of these patients had symptomatic epi-
lepsy, while in one patient seizures were of unknown
etiology. The frontal area was involved by ictal
discharge in two of these.
Three of the ‘symptomatic’ patients reported on
in Table 4 experienced an exacerbation of seizure
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Table 3 Outcome of responders
Patient Outcome Etiology Estimated ictal onset
Total seizures Minor seizures Falling seizures
BO1 ## ### # Cryptogenic Temporal
BO2 ## ## # Cryptogenic Diffuse with temporoparietal onset
BO6 ## """ ## Cryptogenic Temporal
B14 ## ## ## Cryptogenic Frontocentroparietal
BO3 # # # Symptomatic Frontotemporal
BO7 # """ # Symptomatic Temporal
B10 # ### Symptomatic
(Lennox—Gastaut)
Diffuse with frontal l onset
B11 # ## = Cryptogenic Temporal
Difference (D) in seizure frequency: =, D < 20%; "#, D20! 50%; ""##, D50! 75%; """###, D > 75%.frequency and in two of these patients the central
area was involved in ictal discharge. In one case,
however, the total number of seizures and the
number of minor seizures increased, but there
was a dramatic disappearance of falling seizures
to the great satisfaction of the patient. We there-
fore considered this to be a ‘good’ outcome. In this
particular case the onset of ictal activity was found
to be in the temporal zone.
Three of the patients described in Table 4 had a
significant increase of total seizure frequency and of
fallings after VNS. In these cases, the ictal onset was
frontal, frontocentral or diffuse. In one of these
patients there was a dramatic increase in the num-
ber of different seizures after VNS activation and
the patient refused to allow the stimulation to
continue.
The three patients with an electroclinical LNS
showed no significant results from VNS.
The falling seizures of our patients were of dif-
ferent types. In most cases they were tonic, sym-
metric or asymmetric, tonico-postural or tonico-
versive. In three patients, seizures could be
described as atonic and as retropulsive in oneTable 4 Outcome of non responders
Patient Outcome Onset
Total seizures Minor seizures Falling seizures
B04 = = "
B12 = = =
B13 = / =
BO5 " """ ###
BO8 " ### "
B17 " "" "
BO9 """ """ """
B15 "" # ""
B16 "" /
Difference (D) in seizure frequency: =, D < 20%; "#, D20! 50%; "patient. Of the 12 patients whose ictal EEG pattern
we were able to record we found seven cases were
to be focal: three showing an involvement of the
temporal region; three showing an involvement of
the frontal region and the remaining one patient
showing an involvement of the centroparietal. In
five cases, the onset was observed to be diffuse
although in two patients it seemed to be more
indicative of an initial involvement in the temporal
and, then, in the frontal area.
Table 5 shows the results of the effect of VNS
on the outcome of falling seizures. It appears that
retropulsive fallings are more reduced than tonico-
postural seizures, although unfortunately, we do
not have ictal recordings of all epileptic fallings.
Nonetheless, the temporal region does appear to
be involved and in most of the patients we found
a reduced number of recorded falling seizures.
The follow-up data shown in Table 6 indicates
that 5 of the 17 patients are still being treated
with stimulation. In the group of responders, a
second or third implantation was needed by three
patients when the battery became depleted
because of an increase in seizure frequency. TwoEtiology Estimated ictal
Symptomatic Frontal
Unknown (Lennox—Gastaut) Diffuse with frontal
onset
Symptomatic Frontocentral
Symptomatic Centrotemporal
Symptomatic Centroparietal
Symptomatic (Lennox—Gastaut) Diffuse
Cryptogenic Frontocentral
Symptomatic Frontal
Unknown (Lennox—Gastaut) Diffuse
"##, D50! 75%; """###, D > 75%.
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Table 5 Outcome of falling seizures
Patient Seizure type Ictal onset of falling seizures Outcome
B05 Tonic retropulsive Diffuse, more evident temporal ###
B06 Atonic retropulsive Not recorded ##
B14 Retropulsive Not recorded ##
B01 Tonico-postural retropulsive Temporal posterior #
B02 Tonic and atonic Diffuse #
B03 Tonic Frontotemporal #
B07 Atonic retropulsive Not recorded #
B10 Tonic Diffuse, more evident frontocentral #
B11 Tonic Temporal posterior #
B12 Tonic Diffuse =
B13 Tonico-versive Frontocentral =
B04 Tonico-postural Not recorded "
B08 Tonico-postural Centroparietal "
B15 Tonic Frontal "
B17 Atonic Diffuse "
B09 Tonico-postural Frontal """
Difference (D) in seizure frequency: =, D < 20%; "#, D20! 50%; ""##, D50! 75%; """###, D > 75%.patients maintained an unexplainable effect even
after battery depletion had occurred. Three
patients did not feel their seizures significantly
reduced, although their number decreased. So they
refused a new implantation after battery depletion.
In one of them VNS was explanted.Table 6 Follow-up
Patient Outcome Follow-up
B01 Good Battery depletion,
explanted,
effect maintained
B02 Good Battery depletion, followed by
severe worsening of seizure
frequency, reimplanted twice
B03 Discrete Battery depletion, explanted
B04 Unchanged Battery depletion
B05 Good Battery depletion, followed
by worsening of seizures,
reimplanted
B06 Good Committed suicide
B07 Discrete Battery depletion, explanted,
effect maintained
B08 Bad Battery depletion, explanted
B09 Bad Explanted
B10 No significant
changes
Battery depletion
B11 No significant
changes
Battery depletion
B12 Unchanged Battery depletion
B13 Unchanged Dead for pancreatic carcinoma
B14 Good Battery depletion, followed by
worsening of seizures,
reimplanted
B15 Bad Still on
B16 Bad Still on
B17 Bad Turned offIn one patient epilepsy greatly improved after
chronic VNS, but there seemed to be an exacerba-
tion of her behavioral disturbances: her psychiatric
symptoms worsened and she, unfortunately, com-
mitted suicide.
In two patients without results battery deple-
tion has occurred but the stimulator has thus far
not been removed, while in two patients with bad
results the VNS was removed. One patient that did
not seem to respond to VNS also had a pancreatic
carcinoma that led him to his death while VNS was
still active. In one patient, VNS was discontinued
because it seemed to have no effect. In two
patients VNS is still on, but results are bad.
During the first year of stimulation, all anti-epi-
lectic drugs (AEDs) weremaintained at stable levels,
except in the case of one non responder whose
neurologist elected to increase the amount of leve-
tiracetam being used.
In all the other cases, AEDs have been adjusted
during VNS only after the first year and this was
usually done by introducing new medications.Discussion and conclusions
Vagal nerve stimulation (VNS) is known to be an
effective palliative therapeutic alternative in the
treatment of refractory epilepsy.
From precedent studies, VNS at high paradigm
has been demonstrated more effective than at low
paradigm.29 Other studies30 confirmed a long lasting
effectiveness of VNS, increasing in years, with a
23% of 50% of seizure reduction at 3 months after
stimulation onset, reaching 43% at 2 years and
3 months. Further data from different authors are
206 M. Casazza et al.similar: Uthmanet al.24 report 52% of seizure reduc-
tion after 12 years of stimulation, also Murphy31
found a similar reduction in their group of patients.
These percentages are almost the same reported in
the whole literature, to date.15,22,23,25,27 Only Bin-
nie et al.26 reported a lower number of responsive
patients, probably due to the gravity of their
patients. In every published study the indication
is for partial pharmacoresistant epilepsies, while it
does not appear to be an indication that addresses
the ideal candidate for VNS implantation.
There is a noticeable paucity of reliable date on
which kinds of seizures seem to be more responsive
to the VNS therapy. Holmes et al.22 do describe
successful outcomes using VNS in the treatment
of generalized seizures in patients having idiopathic
or symptomatic generalized epilepsy with a signifi-
cant reduction of seizures that involving a fall. But
to our knowledge there are no studies that relate
VNS success to the electrical patterns seen in
responsive seizures.
In this study, we present the results of VNS in 17
patients with partial refractory epilepsy, 16 of which
had experienced epileptic falls that seem to be due
to a secondary synchronization of the focal ictal
discharge. The patients we have reported on in this
study have fallen down from different types of
seizure activity: tonic, tonico-postural, atonic,
although we were not able to obtain electrographic
recordings during all these seizures.
If VNS achieves its effect by desynchronizing
cerebral pathologic discharges, as has been sug-
gested,31 it might therefore be expected to counter-
act any diffuse discharges that lead to a fall or any
secondary generalization. In our study, we observed
our best outcomes with retropulsive tonic seizures
and our worst outcomes with tonico-postural sei-
zures. It is not easy to interpret this outcome, but
tonico-postural seizures are focal frontal seizures
determining a fall, and their location is, in our
series, the less affected by VNS.
Our most successful results were observed in
patients, whose ictal discharge involved at onset
the temporal region and this was usually seen to
occur when there was a very rapid diffusion.
Patients with ictal frontal, central or diffuse dis-
charges consistently were found to have the poorest
results after VNS.
Data from PET studies done on patients with VNS
indicates a decrease in synaptic activity in temporal
structures6 which may suggest a mechanism for this
VNS reduction of seizure activity. Though our find-
ings are consistent with this notion, the size of our
study is by no means sufficient to validate this
hypothesis, which needs a larger series of patients
using EEG ictal studies.Our findings, which indicate that VNS may be
more effective in cryptogenic patients raises inter-
esting questions with respect to symptomatic
patients.
In particular, our patients with LNS did not show
very good results fromVNSwhich seems to contrasts
significantly with much of the data that exists in the
literature on epileptic encephalopathies and parti-
cularly on LNS.32—39 In these studies, the reduction
of seizures in LNS is similar to that of other partial
epilepsies, a reduction of 50% of total seizures is
observed in almost 50% of patients. In only one
study,39 in five of the six children with LNS a reduc-
tion of 90% of seizures is shown, but this was not
furtherly confirmed by other data. The implanted
patients with LNS were all under 18, differently
from our young adult patients having a much longer
illness duration. A correlation between better
response to VNS a higher intelligence levels was
observed.32,34 Our patients, only three, had a clini-
cally observed very low mental age.
For justifying the mean bad results of our series
we think that this discrepancy may be due primarily
to the criteria that have been used to identify
candidates for VNS. In this study, we have only
chosen patients who demonstrate very severe, long
lasting, epilepsy and falling seizures who have been
excluded from surgery or those who have been
operated upon previously but unsuccessfully. In
the other series that have been reported there is
a noticeably higher variability in the duration and
the severity of the epilepsy being studied. Falling
seizures are known to be highly refractory to phar-
macological therapy,28 and our results with VNS
seem to confirm the difficulty that exists in treating
these seizures.
We therefore agree that VNS may be considered
for patients whose epilepsy is refractory and unre-
sponsive to surgical treatment, and suggest to study
where the ictal discharges arise from. Our observa-
tion of ‘‘temporal responders’’ is limited to a very
small series, but the reason why patients with focal
temporal onset of ictal discharge could be the
‘best’ responders may be related to the fact that
vagal efferents are directed to the temporal areas,
possibly inhibiting epileptic discharges. More
extensive studies on electrical ictal pattern of
responsive patients may be able to lead to a more
precise indication for VNS and to more satisfactory
results with this promising therapeutic technique.References
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